Key points are not available for this paper at this time.
Hairy-cell leukemia, a rare B-cell cancer driven by a BRAF mutation and manifesting with cytopenias and splenomegaly, is responsive to purine analogue chemotherapy and to BRAF inhibitors combined with anti-CD20 antibodies.
Falini et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: